Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiromic Biopharma Inc (NQ: KRBP )

1.450 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kiromic Biopharma Inc

< Previous 1 2 3 Next >
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
Kiromic Biopharma, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)
From Robbins LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Kiromic BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – KRBP
From The Rosen Law Firm, P.A.
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)
From Robbins LLP
Via Business Wire
KIROMIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
From Kiromic BioPharma, Inc.
Via Business Wire
NASDAQ:KRBP Shareholder Alert: Investigation over Possible Wrongdoing at Kiromic BioPharma, Inc.
San Diego, CA -- (SBWIRE) -- 05/26/2022 -- Certain directors of Kiromic BioPharma, Inc. are under investigation over potential breaches of fiduciary duties by certain directors. 
Via SBWire
Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma, Inc. (NASDAQ:KRBP) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 04/11/2022 -- Kiromic BioPharma, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic Biopharma Announces Filing of Form 12b-25
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Changes in Management, Board of Directors
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company’s Board of Directors
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Chief Financial Officer Transition
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights
From Kiromic BioPharma
Via Business Wire
Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors
From Kiromic Biopharma, Inc.
Via Business Wire
Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma, Inc. Announces Closing of Public Offering
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma, Inc. Announces Pricing of Public Offering
From Kiromic BioPharma, Inc.
Via Business Wire
KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid Tumors
From Kiromic Biopharma, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.